Dylan Kissane on Muck Rack

Dylan Kissane

Verified
  • Director of Editorial, Labiotech
  • Founder, Scriblr
South Lyon
As seen in: Labiotech, Wiley Online Library, Substack, Business 2 Community, City A.M., Social Media Examiner, EIN News, Beyond Biotech - the podcast from Labiotech (Podcast)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dylan

Contact Dylan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Log in to Buzzsprout

|
By Dylan Kissane Verified
| Labiotech Verified
Are you trying to listen to a podcast? You don't need an account to listen to a podcast episode. 🎙Listen Now
Open in Who Shared Issue with article?

The Naming Patterns Behind 12,000 Biotech Companies

|
By Dylan Kissane Verified
| Labiotech Verified
Photo Credit: Austin Kirk Newsletter Signup - Under Article / In Page "*" indicates required fields This field is for validation purposes and should be left unchanged. Subscribe to our newsletter to get the latest biotech news! By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.* Earlier this month Labiotech published its roundup of the top biotech deals for May 2026.
Open in Who Shared Issue with article?

The Naming Patterns Behind 12,000 Biotech Companies

|
By Dylan Kissane Verified
| EIN News
Earlier this month Labiotech published its roundup of the top biotech deals for May 2026. Heading the list was Angelini Pharma’s $4.1 billion acquisition of Catalyst Pharmaceuticals, just ahead of UCB’s acquisition of Candid Therapeutics for $2.2 billion. For its part, Lilly also acquired Curevo for $1.5 billion, and GSK took over at SiranBio for up to a billion in milestone payments.
Open in Who Shared Issue with article?
See all 79 licensed articles (84 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified